Tyrosine Kinase Inhibitor Withdrawal Syndrome in CML Patients
Some patients will develop (a withdrawal syndrome (WS) after stopping TKI ( around 20% with imatinib, 40% with nilotinib, 40% with dasatinib,...)
ARTICLES
Psychological Factors Affecting the Willingness to Accept a Possible Tyrosine Kinase Inhibitor (TKI) Discontinuation in Chronic Myeloid Leukaemia (CML) Patients
October 31, 2022, Dovepress
Managing Pain After Discontinuing Treatment for Leukemia
June 22, 2022, Physician’s Weekly
Longer treatment duration and history of osteoarticular symptoms predispose to tyrosine kinase inhibitor withdrawal syndrome
July 4, 2019, PubMed
PB1928 Withdrawal syndrome after tyrosine kinase inhibitors discontinuation in patients with chronic myeloid leukemia and deep molecular response in a multicenter prospective study (RU-SKI)
June 2019, Hemasphere
Discontinuation of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia With Losing Major Molecular Response as a Definition for Molecular Relapse: A Systematic Review and Meta-Analysis
May 14, 2019, Frontiers in Oncology
Musculoskeletal Pain in Patients With Chronic Myeloid Leukemia After Tyrosine Kinase Inhibitor Therapy Cessation
May 13, 2019, PubMed
Anxiety and depression associated with tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia
October 23, 2018, PubMed
Symptoms following TKI therapy discontinuation after achieving an adequate response in patients with chronic myeloid leukemia in chronic phase (CML-CP)
June 2018, ASCO 2018
Low body weight and body mass index may be associated with musculoskeletal pain following imatinib discontinuation in chronic myeloid leukemia
April 12, 2017, PublMed
Patient-Reported Quality of Life before and after Stopping Treatment in the ENESTfreedom Trial of Treatment-Free Remission for Patients with Chronic Myeloid Leukemia in Chronic Phase
December 4, 2016, ASH 2016
Cognitive dysfunction after withdrawal of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia
July 28, 2016, American Journal of Hematology
Musculoskeletal Pain in Patients With Chronic Myeloid Leukemia After Discontinuation of Imatinib: A Tyrosine Kinase Inhibitor Withdrawal Syndrome
2014, American Society of Clinical Oncology
Musculoskeletal Pain May Be Sign of Potential Tyrosine Kinase Inhibitor Withdrawal Syndrome in CML
August 1, 2014, The ASCO Post
Musculoskeletal Pain on Stopping Imatinib: Should We Worry?
July 30, 2014, Medscape
Psychological Factors Affecting the Willingness to Accept a Possible Tyrosine Kinase Inhibitor (TKI) Discontinuation in Chronic Myeloid Leukaemia (CML) Patients
October 31, 2022, Dovepress
Managing Pain After Discontinuing Treatment for Leukemia
June 22, 2022, Physician’s Weekly
Longer treatment duration and history of osteoarticular symptoms predispose to tyrosine kinase inhibitor withdrawal syndrome
July 4, 2019, PubMed
PB1928 Withdrawal syndrome after tyrosine kinase inhibitors discontinuation in patients with chronic myeloid leukemia and deep molecular response in a multicenter prospective study (RU-SKI)
June 2019, Hemasphere
Discontinuation of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia With Losing Major Molecular Response as a Definition for Molecular Relapse: A Systematic Review and Meta-Analysis
May 14, 2019, Frontiers in Oncology
Musculoskeletal Pain in Patients With Chronic Myeloid Leukemia After Tyrosine Kinase Inhibitor Therapy Cessation
May 13, 2019, PubMed
Anxiety and depression associated with tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia
October 23, 2018, PubMed
Symptoms following TKI therapy discontinuation after achieving an adequate response in patients with chronic myeloid leukemia in chronic phase (CML-CP)
June 2018, ASCO 2018
Low body weight and body mass index may be associated with musculoskeletal pain following imatinib discontinuation in chronic myeloid leukemia
April 12, 2017, PublMed
Patient-Reported Quality of Life before and after Stopping Treatment in the ENESTfreedom Trial of Treatment-Free Remission for Patients with Chronic Myeloid Leukemia in Chronic Phase
December 4, 2016, ASH 2016
Cognitive dysfunction after withdrawal of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia
July 28, 2016, American Journal of Hematology
Musculoskeletal Pain in Patients With Chronic Myeloid Leukemia After Discontinuation of Imatinib: A Tyrosine Kinase Inhibitor Withdrawal Syndrome
2014, American Society of Clinical Oncology
Musculoskeletal Pain May Be Sign of Potential Tyrosine Kinase Inhibitor Withdrawal Syndrome in CML
August 1, 2014, The ASCO Post
Musculoskeletal Pain on Stopping Imatinib: Should We Worry?
July 30, 2014, Medscape
See also Treatment free remission (TFR)
See also The French trial called STIM (Stop Imatinib)
See also Bone Pain
See also The French trial called STIM (Stop Imatinib)
See also Bone Pain
